Gennady Efimovich Gendlin

Gennady Efimovich Gendlin

Auto-generated profile, based on publicly available information

Gennady Efimovich Gendlin

«N.I. Pirogov Russian National Research Medical University”, Ministry of Healthcare of Russian Federation, Institute of Clinical Medicine

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
GGG. E. Gendlin
G. E. Gendlin
EEE. I. Emelina
E. I. Emelina
INIGOR G. NIKITIN
IGOR G. NIKITIN
VPV. I. Potievskaya
V. I. Potievskaya
ЮВЮ. А. Васюк
Ю. А. Васюк
Методическое письмо для кардиологов учреждений онкологического профиля по профилактике сердечно-сосудистых осложнений противоопухолевой терапии. Междисциплинарный совет по кардиоонкологии, Российское кардиологическое общество

30 October 2021 in Kardiologiia
Verified
Journal Article
Open access
PDF file
IKI. V. Kovtyukh
I. V. Kovtyukh
GGG. E. Gendlin
G. E. Gendlin
INIGOR G. NIKITIN
IGOR G. NIKITIN
ABAzamat Baymukanov
Azamat Baymukanov
ANA. E. Nikitin
A. E. Nikitin
SDS. N. Dvornikova
S. N. Dvornikova
Background Heart damage is one of complications of the novel coronavirus infection. Searching for available predictors for in-hospital death and survival that determine the tactic of managing patients with COVID-19, is a challenge of the present time. Aim To determine the role echocardiographic (EchoCG) parameters in evaluation of the in-hospital prognosis for patients with the novel coronavirus infection, COVID-19. Material and methods The study included 158 patients admitted for COVID-19. EchoCG was performed for all patients. The role of left ventricular (LV) ejection fraction (EF) was analyzed in various age groups. EchoCG data were compared with the clinical picture, including the severity of respiratory failure (RF), blood oxygen saturation (SрО2), data of computed tomography (CT) of the lungs, and blood concentration of troponin. Comorbidity was analyzed, and the highest significance of individual pathologies was determined . Results LV EF ≤40 % determined the worst prognosis of patients with COVID-19 (p<0.0001), including the age group older than 70 years (р=0.013). LV EF did not correlate with the degree of lung tissue damage determined by CT upon admission (р=0.54) and over time (р=0.23). The indexes that determined an adverse in-hospital prognosis to a considerable degree were pericardial effusion (p<0.0001) and pulmonary hypertension (p<0.0001). RV end-diastolic dimension and LV end-diastolic volume did not determine the in-hospital mortality and survival. Blood serum concentration of troponin I higher than 165.13 µg/l was an important predictor for in-hospital death with a high degree of significance (р<0.0001). Th degree of RF considerably influenced the in-hospital mortality (р<0.0001). RF severity was associated with LV EF (р=0.024). The SpO2 value determined an adverse immediate prognosis with a high degree of significance (р=0.0009). This parameter weakly correlated with LV EF (r=0.26; p=0.0009). Patients who required artificial ventilation (AV) constituted a group with the worst survival rate (р<0.0001). LV EF was associated with a need for AV with a high degree of significance (р=0.0006). Comorbidities, such as chronic kidney disease, postinfarction cardiosclerosis and oncologic diseases, to the greatest extent determined the risk of fatal outcome. Conclusion EchoCG can be recommended for patients with COVID-19 at the hospital stage to determine the tactics of management and for the in-hospital prognosis.

31 October 2021 in Наука и здравоохранение
Verified
Journal Article
Open access
ZTZhenisgul Tlegenova
Zhenisgul Tlegenova
BZBekbolat Zholdin
Bekbolat Zholdin
ГГГендлин Г.е.
Гендлин Г.е.
Saule K. BalmagambetovaSaule K. Balmagambetova
Saule K. Balmagambetova
GKGulnara Kurmanalina
Gulnara Kurmanalina
ITIliada Talipova
Iliada Talipova
Введение. Рак молочной железы является чувствительным к определенным схемам химиотерапии, которые оказывают агрессивное действие на сердце и сосуды. Выделяют антрациклин - опосредованную необратимую кардиотоксичность первого типа и трастузумаб - опосредованную обратимую кардиотоксичность второго типа. Определение сывороточных биомаркеров является альтерантивным подходом для ранней оценки дисфункции миокарда. Цель: анализ прогностической значимости тропонина для раннего выявления кардиотоксических осложнений антрациклина и/или трастузумаба у больных раком молочной железы. Стратегия поиска. Поиск осуществлялся в базах данных Pubmed, Web of Science, Scopus, eLIBRARY. Критериями для включения исследований в обзор были: рандомизированные клинические и проспективные исследования, датированные 2010 - 2020 гг.Использовались ключевые слова по следующим разделам: патология: «breast cancer», «breast»; лечение: «antracycline» «trastuzumab», «chemotherapy»; биомаркеры: «troponin», «troponin I», «troponin T», «high sensitive troponin»; осложнения химиотерапии: «cardiotoxicity», исследования: «controlled trial», «randomized controlled trial», «controlled clinical trial», «clinical trial». Отбор исследований производился методом триангуляции. Всего в обзор вошли 27 полнотекстовых исследований, полностью соответствующих критериям поиска. В списке литературы указаны также работы, не соответствовавшие критериям поиска, но иллюстрирующие актуальность темы. Результаты. Повышение уровня тропонина является признаком развития сердечной дисфункции с неблагоприятным прогнозом, особенно при продолжающемся росте уровня тропонина. Прирост уровня тропонина и интеграл прироста от базового уровня являются более надежными предикторами, чем абсолютное значение тропонина. Выводы.Пациенты с РМЖ, получающие терапию антрациклинами и последующую терапию таргетными препаратами имеют наибольшый риск развития кардиотоксических осложнений. Мониторирование уровня тропонина имеет прогностический потенциал и должно проводиться всем пациентам. Панель биомаркеров с включением тропонина может быть более полезной для раннего обнаружения дисфункции миокарда. ntroduction. Breast cancer is sensitive to some schemes of chemotherapy known to be aggressive towards the cardiovascular system. There is anthracycline-mediated irreversible cardiotoxicity of the first type and trastuzumab-mediated reversible cardiotoxicity of the second type. The use of serum biomarkers capable of detecting myocardial injury before symptoms appear is an alternative approach to early diagnosis of the chemotherapy cardiotoxic complications. Aim: analyze the prognostic value of troponin for the early detection of cardiotoxic complications caused by anthracycline and/or trastuzumab in breast cancer patients. Search strategy: The search was carried out across the databases Pubmed, Web of Science, Scopus, e-LIBRARY. Criteria for inclusion in the review were: randomized controlled trials and prospective studies dated 2010–2020. The keywords were used according to the following sections: pathology: "breast cancer", "breast"; treatment: «anthracyclines», «trastuzumab», «chemotherapy»; biomarkers: «troponin», «troponin I», «troponin T», «high sensitive troponin»; complications of chemotherapy: "cardiotoxicity", studies: "controlled trial", "randomized controlled trial", "controlled clinical trial", "clinical trial". The selection of studies was carried out by the triangulation method. In total, the review included full-text 27 studies that completely met the search criteria. The list of references also contains researches that did not meet the search criteria, but illustrating the relevance of the topic. Results. An increase in troponin levels may signify the development of cardiac dysfunction with a poor prognosis, especially if troponin levels continue to rise. The increase in the hs-troponin and the integral of the increase are more reliable predictors than the absolute value of troponin. Сonclusions. Breast cancer patients receiving anthracyclines and subsequent targeted chimiotherapy have the highest risk of cardiotoxic complications. Troponin level monitoring has predictive potential and should be considered to all patients receiving chemotherapy. Troponin and the combination of several markers may turn out to be more sensitive in predicting...

3 May 2020 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
EEE. I. Emelina
E. I. Emelina
AIA. A. Ibragimova
A. A. Ibragimova
IGI. I. Ganieva
I. I. Ganieva
GGG. E. Gendlin
G. E. Gendlin
INIGOR G. NIKITIN
IGOR G. NIKITIN
MSM. Yu. Sitnikova
M. Yu. Sitnikova
Objective Comparative analysis of structural and functional specific features of the heart in patients with toxic cardiomyopathy (TCMP) with a low left ventricular ejection fraction (LVEF) and severe, chronic heart failure (CHF) and in patients with idiopathic dilated cardiomyopathy (DCMP) and similar LVEF and CHF severity. Materials and Methods This observational, single-site study included 15 patients with TCMP (12 of them received treatment including anthracycline antibiotics and 3 patients received targeted therapies) and 26 patients with idiopathic DCMP. Data of echocardiography were compared for patients with TCMP and DCMP with comparably low LVEF of <40 %. Results In patients with severe heart damage associated with antitumor therapy with low LVEF, volumetric and linear indexes of left and right ventricles and the left atrium (left atrial volume index (LAVI), 33.7 (21.5–36.9) ml / m2; right ventricular end-diastolic dimension (RVDd), 2.49 (1.77–3.53) cm; and end-diastolic volume index (EDVI), 78.0 (58.7–90.0) ml / m2) were considerably less than in the DCMP group (LAVI, 67.1 (51.1–85.0) ml / m2; RVDd, 4.05 (3.6–4.4) cm; and EDVI, 117.85 (100.6–138.5) ml / m2, p<0.0001). Furthermore, LV wall thickness and pulmonary artery systolic pressure did not differ in these groups. Both in men and women with TCMP, LAVI and EDVI were significantly less than in men and women with DCMP. Conclusion The study showed significant differences in parameters of cardiac remodeling. In TCMP patients as distinct from DCMP patients, despite a pronounced decrease in LVEF, LV dilatation was absent or LV volumetric parameters were moderately increased with a more severe somatic status.

5 August 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
YVYu. A. Vasyuk
Yu. A. Vasyuk
GGG. E. Gendlin
G. E. Gendlin
EEE. I. Emelina
E. I. Emelina
INIGOR G. NIKITIN
IGOR G. NIKITIN
VPV. I. Potievskaya
V. I. Potievskaya
ЮВЮ. А. Васюк
Ю. А. Васюк
Методическое письмо для кардиологов и терапевтов первичного звена здравоохранения по первичной профилактике сердечно-сосудистых осложнений противоопухолевой терапии. Междисциплинарный совет по кардиоонкологии, Российское кардиологическое общество

1 January 2013
Verified
Journal Article
Closed access
AAA V Anisimova
A V Anisimova
GGGennadiy Gendlin
Gennadiy Gendlin
SBS N Borisov
S N Borisov